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Background:  Streptococcus  pneumoniae  is  a  leading  cause  of  hospitalization  in  HIV-infected  adults
therefore  pneumococcal  vaccine  is  recommended.  The  ideal  antipneumococcal  vaccine  and  effective
vaccination  regimen  remain  controversial  and  needs  further  evaluation.
Methods:  To  assess  the efﬁcacy  of  pneumococcal  vaccines  alone  and  combined,  a randomized,  blinded
clinical  trial  was  conducted  in Brazil  with  331  HIV-patients  aged  18–60,  with  CD4-T  cell  count
≥200 cells/mm3. Two  interventions  60 days  apart  were  done  in three  schedules:  23-valent  pneumococ-
cal  polysaccharide  vaccine  (PPV23)/placebo;  7-valent  pneumococcal  conjugate  vaccine  (PCV7)/placebo;
and  PCV7  plus  PPV23.  Safety  and  reactogenicity  were  evaluated,  and  immunogenicity  was  assessed  by
an IgG  enzyme-linked  immunosorbent  assay  to S. pneumoniae  serotypes  6B, 9V  and  14, performed  at
baseline,  60  and  180 days  after ﬁrst intervention.  Comparison  of  immunogenicity  was  based  on  geomet-
ric  mean  concentration  (GMC),  percentages  of individuals  with  serotype-speciﬁc  IgG  ≥  0.35  g/mL  and
≥1.0  g/mL  and  proportion  of individuals  with  ≥4-fold  increase  in speciﬁc  antibody  concentrations  for
each  serotype.
Results:  Demographic  and HIV  conditions  were similar,  and  both  vaccines  were  well  tolerated  across
vaccine  groups.  Signiﬁcant  increase  in IgG-antibodies  was  observed  to  all serotypes  evaluated.  A greater
proportion  of PCV7  recipients  reached  and  sustained  IgG  antibody  concentrations  at least four  times as
high as  those  at baseline,  for  serotypes  6B  and  9V.  A PPV23  dose  after  PCV7  did  not enhance  immuno-
genicity.
Conclusions: In this  ﬁrst trial  conducted  with  HIV-infected  immunologically  stable  adults  in  South Amer-
ica, both  PPV23  and  PCV7  were  safe  and  immunogenic.  Evidence  suggesting  PCV7  was  more  immunogenic
than  PPV23,  as it  elicited  higher  and persistent  ≥4-fold  increase  of  antibodies  for  6B  and  9V serotypes  in
a  greater  proportion  of  HIV-patients  is noteworthy.  Despite  current  recommendation  of  schedules  com-
bining PCV7  and  PPV23,  there  is little evidence  to  support  this  practice  and  we did  not  observe  beneﬁts
in  this  combination.. Introduction
Invasive pneumococcal disease (IPD), as others bacterial dis-
ases and sepsis represent important causes of hospitalization
n human immunodeﬁciency virus (HIV) patients in the era of
he highly active antiretroviral treatment (HAART) [1,2]. The risk
f IPD in HIV-infected persons is 23–60 times higher than in
∗ Corresponding author at: Divisão de Moléstias Infecciosas e Parasitárias, Hos-
ital  das Clinicas da Faculdade de Medicina da USP, Avenida Dr. Enéas de Carvalho
guiar, 255, 4◦ andar, São Paulo, São Paulo BR 05403-000, Brazil.
el.: +55-11-26616530.
E-mail address: hoyehli@yahoo.com.br (Y.-L. Ho).
264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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HIV-uninfected individuals [3,4], even in the HAART era [5], and
the mortality is also higher for HIV-infected adults [3,4]. Therefore,
strategies to reduce the burden of IPD are crucial.
The 23-valent pneumococcal polysaccharide vaccine (PPV23),
although recommended for HIV-infected adults, presents lower
immunogenicity and effectiveness than to HIV-uninfected persons.
Clinical trials showed impaired antibody response to PPV23 in
HIV-infected patients compared to healthy individuals [6]. Addi-
tionally, antibody responses may  be CD4-T cell dependent [7,8],
making PPV23 administration preferential in the early course of HIV
infection, when CD4-T cell counts are ≥200 cells/mm3 [9], or after
immune restoration through HAART. According to a meta-analysis
[10], PPV23 was  not effective in reducing IPD-related mortality
rates in adults, even in populations for whom PPV23 is currently
4 ine 31
r
m
a
m
b
s
p
t
e
i
r
b
≥
f
e
n
w
o
i
P
b
w
i
P
a
w
p
P
2
2
g
H
d
u
f
(
v
(
d
C
p
e
t
g
2
C
(
A
b
b
d
s
o
o048 Y.-L. Ho et al. / Vacc
ecommended, despite vaccine protection for presumptive pneu-
ococcal pneumonia and for all-cause pneumonia. In HIV-infected
dults, conﬂicting results about PPV23 efﬁcacy against IPD, pneu-
ococcal pneumonia and other bacterial pneumonia have also
een observed [11–18].
The use of pneumococcal conjugate vaccine (PCV) in adults is
till controversial [19,20]. Some clinical trials in nonimmunosup-
ressed adults revealed higher antibody responses to PCV than
o PPV23 [21–23], while inferior antibody response to PCV in
lderly individuals was observed [24]. In a clinical trial compar-
ng PPV23 and PCV in HIV-infected adults [25], higher antibody
esponses were observed after PCV for serotypes 6B, 18C, and 23F,
ut not for 19F. In HIV-infected adults with CD4-T cells counts
200 cells/mm3, no difference was found between PPV23 and PCV
or serotypes 4, 6B, 9V, 14, and 23F [26]. In one of the few studies
valuating the effectiveness of PCV in HIV-infected adults [27], sig-
iﬁcant protection against recurrence of IPD in HIV-infected adults
as observed, however, this protection has decreased dramatically
ver time, from 85% in the ﬁrst year to 25% thereafter.
Combined PCV/PPV23 schedules have been tested for HIV-
nfected adults. Two PCV doses given a month apart, followed by
PV23 nine months later, elicited signiﬁcant increment of anti-
ody concentration [28]. Lesprit et al. [29] observed in HIV-adults
ith CD4-T cell counts of 200–500 cells/mm3 higher immunolog-
cal response to PCV followed by PPV23 compared to one dose of
PV23, while no difference was observed between two  doses of PCV
nd PCV/PPV23 schedules. On the other hand, no antibody increase
as seen in a study [26] using PCV followed by either conjugate or
olysaccharide vaccine.
This study aims to compare antibody response to PPV23 and
CV7 alone and combined in HIV-infected adults.
. Materials and methods
.1. Study design
A randomized, blinded clinical trial to compare the immuno-
enicity of PPV23 and PCV7 given in different schedules to
IV-infected adults was performed. Patients received two vaccine
oses given 60 days apart, according to three vaccination sched-
les, as follows: PPV23 and then placebo vaccine (group A); PCV7
ollowed by placebo vaccine (group B); and PCV7 followed by PPV23
group C). To assess vaccine-induced immune responses, peripheral
enous blood samples were collected just before each vaccine dose
at baseline and day 60), and on day 180 (120 days after second
ose). Simultaneously, blood samples were collected to perform
D4-T cells count and HIV viral load tests.
Sample size calculations, with a signiﬁcance level of 0.05, a
ower of 0.80, and 10% loss to follow-up resulted in 140 patients in
ach group. Allocation to groups was on 1:1:1 basis generated by a
able of random numbers from Epi-Info version 6.04. Study investi-
ators and laboratorial executors were blinded to group allocation.
.2. Study population
HIV-infected outpatients were recruited at the Hospital das
línicas da Faculdade de Medicina da Universidade de São Paulo
HCFMUSP), São Paulo, Brazil, the largest public hospital in South
merica. Individuals aged 18–60, with HIV infection documented
y enzyme-linked immunosorbent assay (ELISA) and Western-
lot testing, and with CD4-T cell count ≥200 cells/mm3 in two
ifferent occasions in the past six months were eligible. Exclu-
ion criteria included: any acute febrile illness at the moment
f vaccination, active AIDS-deﬁning clinical condition, previ-
us immunization with any of the pneumococcal vaccines, any (2013) 4047– 4053
systemic malignancy neoplasm, use of immunoglobulin within the
last three months, current pregnancy and antecedent of allergy to
any of the pneumococcal vaccine components.
The study was  approved by the Ethics Committee at HCFMUSP
(process number 047/04). The trial is registered in clinical trial reg-
ister/database under the number RBR-3P7577. Written informed
consent was obtained from all participants. Principles of Decla-
ration of Helsinski were followed and the study was conducted
adhering to good clinical practice guidelines.
After screening, individual interview was  performed and medi-
cal record was  reviewed to obtain demographic characteristics and
information related to HIV infection.
2.3. Vaccine administration
PPV23 (Pneumovax; Aventis Pasteur) contained 25 g/dose of
Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.
PCV7 (Prevenar; Wyeth) contained per dose 2 g of pneumococcal
serotypes 4, 9V, 14, 18C, 19F, 23F and 4 g of serotype 6B individ-
ually conjugated to diphtheria CRM197 protein. Placebo vaccine
consisted of physiological saline solution. Doses of 0.5 mL  were
administered by research nurses as deltoid-intramuscular injec-
tions.
2.4. Immunogenicity
Pneumococcal serotypes 6B, 9V, and 14 were selected for
immunogenicity studies based on IPD data in adults [30] and on
pneumococcal carriage by HIV-infected adults living in São Paulo
[31] at the time this study was designed. They were among the most
frequently isolated both from IPD and carriage and are common to
both vaccines.
Total IgG anticapsular antibody concentrations to serotypes
6B, 9V, and 14 were measured by ELISA, according to the World
Health Organization protocol [32]. In order to avoid assay vari-
ability, same lot microtiter plates, capsular and C-polysaccharides,
and enzyme-conjugated anti-human IgG were used throughout
this study. Before the analysis, both optimal antigen coating con-
centration and enzyme-conjugated anti-human IgG dilution were
determined. Serum samples, aliquoted and stored at −70 ◦C until
assayed, were reacted with pneumococcal C-polysaccharide and
22F capsular polysaccharide to adsorb antibodies to common con-
taminants that might be present in the coating antigens. Every
ELISA plate contained a pooled human serum sample from vac-
cinated individuals as quality control and eight duplicate dilutions
of a calibration standard, 89-SF (not adsorbed with serotype 22F
polysaccharide). All serum samples belonging to a patient were
analyzed simultaneously on the same plate, in duplicate and in six
serial dilutions.
Antibody concentrations were calculated by comparing test sera
with 89-SF using a four-parameter curve ﬁt program from ELISA
software [33]. Results were expressed as g/mL calculated on the
basis of the assigned IgG values for 89-S reference serum [34,35].
Samples with antibody concentrations <0.1 g/mL or >100 g/mL
were conﬁrmed upon retesting.
2.5. Statistical analysis
The pre- and post-vaccine antibody concentrations against each
serotype were log transformed to obtain normality, and the results
expressed as geometric mean concentration (GMC).
The following parameters were calculated: (a) GMCs for
serotypes 6B, 9V and 14; (b) the percentages of individuals with
serotype-speciﬁc IgG ≥ 0.35 g/mL and ≥1.0 g/mL; (c) proportion
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Table 1
Baseline characteristics of the study population at time of inclusion.
Group A (N = 111) Group B (N = 110) Group C (N = 110) p
Male, n (%)a 77 (69.5) 86 (78.2) 84 (76.4) 0.28
Age,  mean ± SDb 40.16 ± 9.41 40.12 ± 8.51 41.55 ± 7.76 0.37
AIDS*, n (%)a 65 (58.6) 65 (59.1) 69 (62.7) 0.79
CD4-T cells, mean ± SDc 548 ± 304 545 ± 238 492 ± 269 0.07
HIV  viral load <400 copies/mm3, n (%)a 71 (64) 74 (67.3) 79 (72.5) 0.39
HAART, n (%)a 81 (73) 84 (76.4) 89 (80.9) 0.38
SD, standard deviation; AIDS, acquired immunodeﬁciency syndrome-deﬁning clinical condition; HAART, highly active antiretroviral therapy.
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aa Chi-squared test.
b ANOVA.
c Kruskal–Wallis.
f individuals with ≥4-fold increase in antibody concentrations for
ach serotype.
The values of 0.35 g/mL and 1.0 g/mL chosen as cut-off points
o not necessarily correspond to seroprotective levels. Despite
.35 g/mL has been deﬁned as the correlate of protection against
PD in infant, no seroprotective level has yet been established for
dults.
Microsoft Excel 2003 was used to enter all data and statis-
ical analysis was performed using Epi-Info v3.5.1 and StatPlus
rofessional v5.8.4. Differences between groups in proportion of
ndividuals with IgG ≥ 0.35 g/mL, IgG ≥ 1.0 g/mL, and ≥4-fold
ncrease in antibody concentrations were determined by two-
ailed Fisher exact and Pearson Chi-squared tests. Medians were
ompared using ANOVA or Kruskal–Wallis tests. The level of sig-
iﬁcance was set at p ≤ 0.05, with 95% conﬁdence intervals (CI).
. Results
.1. Study population
From October 2005 to May  2009, 331 patients were enrolled
n the study (111 individuals to group A, 110 to group B and
10 to group C). Enrollment was interrupted because institution
verloading prevented further admissions of recently diagnosed
IV-patients. There was no differential loss to follow-up among
tudy groups (Fig. 1).
Mean age of patients was 40.6 years, 74.6% male, mean time of
IV diagnosis was 6.7 years, and 60.1% had previous AIDS-deﬁning
linical condition. Mean of CD4-T cells count was 525 cells/mm3
nd 67.3% had HIV-viral load <400 copies/mm3. HAART was  in use
y 76.6% of patients. The three groups were similar in demographic
haracteristics and HIV conditions (Table 1).
.2. Immunogenicity
At baseline there were no signiﬁcant differences among the
hree groups in GMCs of antipneumococcal antibodies or in
he proportion of individuals with IgG antibody concentration
0.35 g/mL or ≥1.0 g/mL for all serotypes analyzed (Table 2).
Sixty days after the initial dose of either PPV23 (group A) or PCV7
groups B and C), all study groups showed signiﬁcant increases in
MCs of the antipneumococcal antibodies for all serotypes (Fig. 2).
t day 180, the antibody levels decreased in all groups for all
erotypes, though less markedly for serotypes 6B and 14 in recip-
ents of a PCV7 dose and PPV23 booster 60 days later (group C)
Fig. 2).
The mean concentration of antipneumococcal antibodies and
he proportion of individuals with antibody concentrations
0.35 g/mL and ≥1.0 g/mL 60 and 180 days post-vaccination
ere similar for the three serotypes analyzed. However, the pro-
ortion of individuals who achieved at least a 4-fold increase in
ntibody levels was higher to serotypes 6B and 9V in patientsprimed with PCV7 (groups B and C), in both 60 and 180 days
(Table 2).
No statistical differences were observed after receipt of PCV7
alone (group B) compared with a PPV23 dose 60 days after PCV7
priming (group C) as measured by antipneumococcal antibody
GMCs, proportion of individuals with IgG antibody concentrations
≥0.35 g/mL or ≥1.0 g/mL, or presenting ≥4-fold increases in
antibody levels (Table 2).
3.3. Reactogenicity
All strategies were well tolerated. No severe local or systemic
symptoms were reported. After ﬁrst vaccination, no statistical
difference was observed between PPV23 and PCV7 in terms of
local reaction, as pain, redness and swelling at the injection site.
However, higher proportion of individuals vaccinated with PCV7
reported systemic symptoms, including fever, myalgia and asthe-
nia (Table 3). No statistical difference was observed between PPV23
given alone (group A) or as a booster dose (group C).
4. Discussion
The role of pneumococcal vaccination and the best antipneumo-
coccal vaccine to be recommended in adults is still controversial
[19,20]. Recently, a pneumococcal 13-valent conjugate vaccine
(PCV13) was approved in the USA for people aged ≥50 years and
the Advisory Committee on Immunization Practices of USA (ACIP)
recommended routine use of PCV13 for adults aged ≥19 years with
immunocompromising conditions [36]. However, many questions
about the use of pneumococcal vaccines are still unclear [37]. Fur-
thermore, different from infants, the protective speciﬁc antibody
concentration in adults is not determined. Questions as the best
condition and the ideal schedule of vaccination of HIV-infected
adults, and the lower post-vaccination responses than by immuno-
competent individuals are otherwise unresolved problems [38–41].
Despite only patients with CD4-T cell ≥200 cells/mm3 have been
enrolled, some studies observed no impact of CD4-T count on
PPV23 immunogenicity and determined the potential inﬂuence of
antiretroviral therapy and HIV-viral load at the moment of vacci-
nation with protective effect [14–16]. In our trial, the majority of
patients was  in current antiretroviral therapy and had HIV-viral
load <400 copies/mm3.
Antibodies levels at baseline were high to the three serotypes,
especially to serotype 14, what might in part explain the absence
of signiﬁcant differences after vaccination, in terms of fre-
quency of individuals with antibody concentrations ≥0.35 g/mL
or ≥1.0 g/mL. Therefore, analysis of immunogenicity based on
these two parameters may  be of little value for some populations
and age groups unlikely to be naive to pneumococcal antigens.
The ﬁnding that the proportion of individuals who reached a
≥4-fold increase in antibodies levels 60 days from baseline was
higher in recipients of PCV7 may  imply superior immunogenicity
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Table 2
Serum IgG antibodies responses to pneumococcal capsular polysaccharides serotypes 6B, 9V, and 14 from HIV-infected adults before and after pneumococcal vaccines given in three vaccine schedules.
Serotype Serum sample Mean IgG
concentrationa, g/mL
(CI95%)
IgG concentrationa
≥0.35 g/mL, N (%)
IgG concentrationa
≥1.0 g/mL, N (%)
IgG fold increasea ≥4, N
(%)
A B C A B C A B C A B C
6B Preb 0.73 (0.56–0.94) 0.51 (0.39–0.65) 0.57 (0.44–0.74) 76 (68.5) 68 (62.4) 70 (63.6) 46 (41.4) 29 (26.6) 40 (36.4) n/a n/a n/a
60  daysc 1.45e (1.04–2.01) 1.88e (1.35–2.64) 2.12e (1.49–3.01) 74 (74.0) 81 (81.0) 88 (83.8) 58 (58.0) 63 (63.0) 67 (63.8) 13 (13.0) 42 (42.0) 38 (36.2)**
180 daysd 1.02f (0.73–1.42) 1.24f (0.88–2.50) 1.76f (1.24–2.5) 67 (75.3) 74 (81.3) 76 (83.5) 47 (52.8) 45 (49.5) 54 (59.3) 7 (7.9) 27 (30.0) 27 (29.7)**
9V Pre 0.55 (0.43–0.69) 0.43 (0.33–0.55) 0.47 (0.38–0.58) 75 (67.9) 59 (54.1) 64 (58.2) 29 (26.1) 32 (29.4) 25 (22.7) n/a n/a n/a
60  days 1.76e (1.34–2.31) 2.74e (2.00–3.77) 2.97e (2.18–4.03) 90 (90.0) 89 (89.0) 97 (92.4) 69 (69.0) 74 (74.0) 78 (74.3) 42 (42.0) 58 (58.0) 66 (62.9)*
180 days 1.37f (1.03–1.82) 1.68f (1.22–2.31) 2.13f (1.58–2.88) 79 (88.8) 77 (84.6) 81 (89.0) 56 (62.9) 55 (60.4) 60 (65.9) 25 (28.1) 41 (45.6) 41 (45.1)*
14 Pre 1.82 (1.36–2.42) 1.15 (1.08–2.16) 1.40 (1.01–1.91) 95 (85.6) 86 (78.9) 84 (76.4) 70 (63.1) 64 (58.7) 60(54.4) n/a n/a n/a
60  days 8.94e (6.36–12.58) 12.36e (8.15–18.74) 8.01e (5.70–11.26) 96 (96.0) 89 (89.0) 101 (96.2) 92 (92.0) 88 (88.0) 92 (87.6) 46 (46.0) 62 (62.0) 54 (51.4)
180  days 6.72f (4.65–9.72) 9.32f (6.04–14.38) 6.35f (4.36–9.26) 86 (96.6) 81 (89.0) 86 (94.5) 79 (88.8) 76 (83.5) 77 (84.6) 35 (39.3) 50 (55.6) 42 (46.2)
CI denotes conﬁdence interval.
A  denotes group A, comprising persons vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPV23) and placebo 60 days apart.
B  denotes group B, vaccinated with pneumococcal 7-valent conjugate vaccine (PCV7) and placebo 60 days apart.
C  denotes group C, in which persons were vaccinated with PCV7 followed by PPV23 60 days apart; n/a denotes not applicable.
Differences in means of IgG investigated by analysis of variance; else, by Pearson’s Chi-square.
a Concentrations calculated in geometric mean.
b Pre-vaccination, N = 111 (group A), 109 (group B, 1 sample accidentally lost), 110 (group C).
c 60 days after 1st vaccine, N = 100 (groups A and B, 2 samples accidentally lost), 105 (group C).
d 180 days after 1st vaccine, N = 89 (group A), 91 (group B), 91 (group C, 1 sample accidentally lost).
e p < 0.05 for pre-vaccination vs 60 days.
f p < 0.05 for pre-vaccination vs 180 days.
* p < 0.05 for group A vs groups B and C.
** p < 0.001 for group A vs groups B and C.
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331 paent s enrolled
Grou p A (PPV23)
N=111
Visit  2
N=102
89 paent s 
concluded 
trial
5 with drew co nsent 
7 were lost to  follow -up
1 died 
3 with drew co nsent 
5 were lost to  follow -up
1 died 
Grou p B  (PCV7)
N=110
Visit  2
N=102
91 paent s 
conclu ded 
trial
2 with drew co nsent 
9 were  lost to  fol low -up
3 with drew co nsent
5 were  lost to  fol low -up
Grou p C (PCV7  + PPV23)
N=110
Visit  2
N=105
92 paent s 
conclu ded 
trial
3 with drew co nsent 
10 were  lo st to  fol low -up
3 with drew co nsent 
2 were  lost to  fol low -up
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aig. 1. Enrollment and follow-up visits. Group A: vaccinated with 23-valent pneu
-valent pneumococcal conjugate vaccine and placebo 60 days after. Group C: va
olysaccharide vaccine 60 days after.
nduced by a single dose of PCV7 compared with PPV23. Our ﬁnd-
ng is in contrast with a recent study [42] using a different clinical
rial design, in which 2-fold increases in antibody concentration
etween PCV7 and PPV23 were similar.
Decline in antibody concentrations 180 days after initial dose
as similar and expectedly slight for all vaccine schedules. Interest-ngly again was the signiﬁcant larger proportion of PCV7 recipients
eeping higher serotypes 6B and 9V anticapsular antibody incre-
ents than those primed with PPV23. Consistent with previous
ig. 2. Mean concentration and 95% conﬁdence intervals (CIs) of serum IgG antibodies re
nfected adults before (pre), 60 days (60 d), and 180 days (180 d) after initial pneumococ
rror  bars are CIs for group A, solid bar ending with an horizontal dash, CI for group B a
rst  (pre) and second (60 d) injection; stars, times of blood collection; §, signiﬁcant higher
nalysis  of variance.ccal polysaccharide vaccine and placebo 60 days apart. Group B: vaccinated with
ted with 7-valent pneumococcal conjugate vaccine and 23-valent pneumococcal
reports [26,42] but in contrast with another study [29], we observed
no beneﬁt of booster with PPV23 after priming with PCV7.
Similar to previous studies [26,28,29], both vaccines were well
tolerated. Systemic symptoms were more frequent after receipt of
PCV7 than of PPV23, as observed in prior study [42], but in con-
trast with other [26]. Previous exposition to PCV7 did not alter the
reactogenicity to PPV23, as reported earlier [28].
Limitations of our study comprise the narrow subset of
vaccine serotypes evaluated, though they represent the most
sponses to capsular Streptococcus pneumoniae serotypes 6B, 9V, and 14 from HIV-
cal vaccine doses, given in three vaccination schedules (groups A, B and C). Dashed
nd error bars ending with closed circles, CIs for group C; arrows indicate times of
 geometric mean concentrations (p < 0.05) than at pre (baseline) for each group per
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Table 3
Subjects reporting local reactions or systemic symptoms.
Local reaction, n (%) Systemic symptoms, n (%)
Prime PPV23 vs PCV7
PPV23 43 (39.1) 27 (24.5)
PCV7 90 (41.3) 77 (35.3)
Prime PPV23 vs PPV23 after PCV7
PPV23 43 (39.1) 27 (24.5)
PPV23 after PCV7 29 (28.3) 18 (17.5)
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[PV23, 23-valent pneumococcal polysaccharide vaccine; PCV7, pneumococcal 7-
alent conjugate vaccine.
ommon serotypes causing IPD in adults in Brazil [30]. Evalu-
ting vaccine-induced antibodies to more serotypes would add
urther information on the immunogenicity elicited by different
accine schedules. Functional antibody activity, as measured by
psonophagocytic assay, was not assessed in our trial, however,
revious studies have demonstrated that adsorbing test sera with
neumococcal 22F capsular polysaccharide improves correlation of
gG-ELISA with opsonophagocytic activity [43–45].
A major problem in immunogenicity trials in adults is the lack
f a deﬁned level of antibodies that correlates with disease preven-
ion. Although IgG antibody levels ≥1.0 g/mL for the majority of
erotypes is required for protection in children [46], this is indef-
nite in adults, and the best method to determine post-vaccine
erological turning is still controversial.
In conclusion, this ﬁrst pneumococcal vaccine trial in HIV-
nfected adults immunologically stable conducted in South America
howed both PPV23 and PCV7 elicited signiﬁcant increase of IgG
ntibodies to serotypes 6B, 9V, and 14. PCV7 provided higher pro-
ortion of individuals who reached 4-fold increase of IgG and
ustained this condition to serotypes 6B and 9V. Despite current
ecommendation of schedules combining PCV7 and PPV23 [38],
here is little evidence to support this practice and we did not
bserve beneﬁt in this combination. Both vaccines were well toler-
ted in HIV-infected adults.
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